Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
Statins are the accepted standard for lowering low-density lipoprotein-cholesterol (LDLC). However, 5%-10% of statin-treated patients report intolerance, mostly due to musclerelated adverse effects. There are challenges to objective identification of patients with statin intolerance. Evolocumab is a...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
Wiley
2016
|